Table 5.
Showing the effect of management on dose/frequency of conventional drug at 3rd and 6th month as compared to 0 day.
| Conventional Medicine given at 0 day | Effect of the integrated approach |
||||||
|---|---|---|---|---|---|---|---|
| Dose/frequency reduction |
Medicine stopped |
||||||
| Group I | Group II | ap-value | Group I | Group II | ap-value | ||
| After 3 months | A | 27 (10.1) | 188 (32.0) | <0.00001 | 29 (10.8) | 77 (13.1) | 0.347 |
| B | 8 (33.3) | 19 (31.7) | 0.880 | 4 (16.7) | 10 (16.7) | 1.000 | |
| C | 43 (33.6) | 168 (32.9) | 0.888 | 4 (3.1) | 84 (16.5) | 0.0001 | |
| D | 24 (28.9) | 21 (17.2) | 0.046 | 2 (2.4) | 2 (1.6) | 0.696 | |
| E | 1 (12.5) | 63 (42.9) | 0.089 | 0 (0.0) | 9 (6.1) | 0.471 | |
| Total | 103/511 (20.1%) | 459/1427 (32.2%) | <0.001 | 39/511 (7.6%) | 182/1427 (12.7%) | 0.001 | |
| After 6 months | A | 64 (23.9) | 170 (28.9) | 0.126 | 46 (17.2) | 225 (38.3) | <0.00001 |
| B | 6 (25.0) | 17 (28.3) | 0.756 | 8 (33.3) | 23 (38.3) | 0.667 | |
| C | 65 (50.8) | 190 (37.3) | 0.005 | 12 (9.4) | 169 (33.1) | <0.00001 | |
| D | 33 (39.8) | 33 (27.0) | 0.056 | 11 (13.3) | 39 (32.0) | 0.002 | |
| E | 1 (12.5) | 23 (15.7) | 0.810 | 0 (0.0) | 67 (45.6) | 0.011 | |
| Total |
169/511 (33.1%) |
433/1427 (30.3%) |
0.254 |
77/511 (15.1%) |
523/1427 (36.6%) |
<0.001 |
|
| Drug Change |
No reduction |
||||||
| Group I |
Group II |
ap-value |
Group I |
Group II |
ap-value |
||
| After 3 months | A | 33 (12.3) | 44 (7.5) | 0.022 | 179 (66.8) | 279 (47.4) | <0.00001 |
| B | 4 (16.7) | 8 (13.3) | 0.696 | 8 (33.3) | 23 (38.3) | 0.667 | |
| C | 9 (7.0) | 37 (7.3) | 0.928 | 72 (56.3) | 221 (43.3) | 0.008 | |
| D | 7 (8.4) | 18 (14.8) | 0.173 | 50 (60.2) | 81 (66.4) | 0.368 | |
| E | 0 (0.0) | 26 (17.7) | 0.193 | 7 (87.5) | 49 (33.3) | 0.001 | |
| Total | 53/511 (10.4%) | 133/1427 (9.3%) | 0.490 | 316/511 (61.8%) | 653/1427 (45.7%) | <0.001 | |
| After 6 months | A | 35 (13.1) | 44 (7.5) | 0.009 | 123 (45.9) | 149 (25.4) | <0.00001 |
| B | 6 (25.0) | 11 (18.3) | 0.490 | 4 (16.7) | 9 (15.0) | 0.849 | |
| C | 15 (11.7) | 21 (4.1) | 0.0008 | 36 (28.1) | 130 (25.5) | 0.222 | |
| D | 9 (10.8) | 18 (14.8) | 0.417 | 30 (36.1) | 32 (26.2) | 0.128 | |
| E | 0 (0.0) | 44 (29.9) | 0.067 | 7 (87.5) | 13 (8.8) | <0.00001 | |
| Total | 65/511 (12.7%) | 138/1427 (9.6%) | 0.053 | 200/511 (39.1%) | 333/1427 (23.3%) | <0.001 | |
Values have been expressed as n (%).
A = Amlodipine, B = Atenolol, C = Amlodipine + Atenolol, D = Losartan, E = Telmisartan.
n (Group I – Amlodipine) = 268, n (Group I – Atenolol = 24), n(Group I – Amlodipine + Atenolol) = 128, n (Group I – Losartan) = 83, n (Group I – Telmisartan) = 8, n (Group II – Amlodipine) = 588, n (Group II – Atenolol = 60), n (Group II – Amlodipine + Atenolol) = 510, n (Group II – Losartan) = 122, n (Group II – Telmisartan) = 147.
a
Compared using two sample proportion test.